Company: STAA
Filing Date: 2025-12-16
Form Type: DFAN14A
Source: 0001213900-25-122330
Chunk: 6

Company: STAAR SURGICAL CO
Filing Date: 2025-12-16
Form: DFAN14A
Chunk 6
---
 Shareholder
Meeting will have no effect on the outcome of the Proposed Merger Special Meeting. The Participants do not believe that there is any lawful
reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder
vote at the Proposed Merger Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise
challenge, the Participants’ ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE.The
definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company’s shareholders
and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on November 21, 2025 and is available here.

Contacts

Investor Contacts

John Ferguson / Joseph Mills

Saratoga Proxy Consulting LLC

jferguson@saratogaproxy.com

jmills@saratogaproxy.com

(212) 257-1311

(888) 368-0379

Media Contacts

Scott Deveau / Jeremy Jacobs

August Strategic Communications

Broadwood@AugustCo.com

(323) 892-5562

Exhibit 2

Exhibit 3

<div align='center'>Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory</div>

HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited
(together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder
of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR
shareholders